demonstrated in a glioblastoma mouse model that anti-EGFRvIII CAR NK cells engineered to produce CXCR4 displayed selective chemotaxis towards CXCL12/SDF1-secreting glioblastoma cells, resulting in enhanced tumor regression and survival (62).Besides, the modification of NKG2D CAR NK cells to express CXCR1 significantly increased anti-tumor responses in murine peritoneal ovarian cancer xenografts (63). The gene discussed is KLRK1; the disease is neoplasm.